Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Kinesin family member 20B (
KIF20B
, also known as MPHOSPH1) is a kinesin protein that plays a critical role in cytokinesis. Previously, we and others have demonstrated the oncogenic role of
KIF20B
in several cancers; however, the exact mechanisms underlying its tumorigenic effects remain unclear. Herein, we showed overexpression of
KIF20B
in human
hepatocellular carcinoma
(
HCC
) and reported a negative correlation between
KIF20B
level and prognosis of patients. Mechanistically, reducing
KIF20B
blockades mitotic exit of
HCC
cells at telophase in a spindle assembly checkpoint independent way. Importantly, reducing
KIF20B
acts synergistically with three microtubule-associated agents (MTA) to p53- or p14ARF-dependently suppress p53-wt or p53-null
HCC
cells. In addition to taxol, reducing
KIF20B
also enhanced the toxicity of two chemotherapeutic drugs, hydroxycamptothecin and mitomycin C. In conclusion, we found a novel mechanism in that blocking cytokinesis by
KIF20B
inhibition increases the efficacy of MTA; our results thus suggested a dual-mitotic suppression approach against
HCC
by combining MTA with
KIF20B
inhibition, which simultaneously blocks mitosis at both metaphase and telophase.
...
PMID:Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule-targeting agents by blocking cytokinesis. 3019 36